Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of once-weekly GZR102 versus once-every-2-weeks GZR18 in type 2 diabetes mellitus with inadequate glycemic control
CTR20252305Phase 2Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Aug 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of GZR102, bofanglutide in type 2 diabetes mellitus (T2DM), sponsored by Gan & Lee Pharmaceuticals. Started Aug 2025; status: completed.
02
Drugs
GZR102bofanglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20252305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252305.